[Press Release – Please see Disclaimer]
Molecule, a decentralised biopharma marketplace, has developed a novel IP-to-NFT framework with Web3 technology innovator Nevermined. In a historic transaction, the first biopharma IPNFT was successfully transferred to research collective VitaDAO to fund novel longevity therapeutics at the University of Copenhagen.
18th August 2021, Basel, Switzerland — For the first time in history, NFTs are being used for a transfer of IP ownership in medical research. This unique milestone is a result of a partnership between biopharma IP marketplace Molecule, and VitaDAO, a decentralized collective (DAO) funding longevity research, and the University of Copenhagen. This innovation is enabled by a groundbreaking data storage solution developed by web3 technology innovator Nevermined.
VitaDAO, Nevermined and Molecule Overcome Biopharma Industry Challenges
Early-stage biopharma research is the lifeblood that fuels advances in medicine. However, many domain
Global search interest for ‘NFT’ surpasses ‘crypto’ for the first time ever
Cointelegraph Research predicts that nonfungible token sales could eclipse $17.7 billion by the end of 2021. For the…